InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

InspireMD Stock Down 16.9 %

Shares of NSPR opened at $2.76 on Monday. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.85. The firm’s 50 day moving average price is $2.58 and its 200 day moving average price is $2.51. The company has a market cap of $68.81 million, a P/E ratio of -3.63 and a beta of 0.96.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.06). InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. The business had revenue of $1.51 million for the quarter, compared to analysts’ expectations of $1.38 million. During the same period in the previous year, the company earned ($0.53) earnings per share. Research analysts forecast that InspireMD will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NSPR. McKinley Carter Wealth Services Inc. acquired a new stake in InspireMD during the 4th quarter worth $28,000. Mesirow Financial Investment Management Inc. acquired a new stake in InspireMD during the 1st quarter worth $71,000. Finally, Rosalind Advisors Inc. boosted its stake in InspireMD by 266.4% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after purchasing an additional 1,827,579 shares during the period. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.